Pre-made Daclizumab biosimilar ( Whole mAb, anti-IL2RA therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-129
Anti-IL2RA therapeutic antibody (Pre-made Daclizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL2RA therapeutic antibody (Pre-made Daclizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||3nfs:HL/3nfp:HL:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma|
|Conditions Approved||Renal transplant rejection|
|Conditions Active||Multiple sclerosis|
|Conditions Discontinued||Asthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis|
|Development Tech||GS Gene Expression System|